Provided are recombinant anti-CD70 antibodies, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells. The antibody could be used for the prophylaxis or treatment of CD70-expressing cancers and immunological disorders where CD70-expressing cells are present.
Figure 1 Subcellular localization, microtubule-disrupting, and anti-mitotic activities of 1F6 ADCs.
786-O cells were treated with the indicated mAb, ADCs, or free AFP. Microtubule organization was examined by an anti-a-tubulin antibody and counterstained with AF488-conjugated goat anti-mouse IgG while nuclei were counterstained with DAPI. One to three representative cells from each treatment are shown.
Law, C. L., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., ... & Sauter, G. (2006). Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Research, 66(4), 2328-2337.
Figure 2 Subcellular localization, microtubule-disrupting, and anti-mitotic activities of 1F6 ADCs.
Cell cycle distribution and DNA synthesis in 786-O cells at progressive time points after m1F6, m1F6-vcAFP8, or IgG-vcAFP8 treatment was determined by anti-bromodeoxyuridine and propidium iodide staining and flow cytometry. G0-G1, S, G2-M, and apoptotic events were defined on the dual-color dot plots as described before. Percentages of cells in different phases of the cell cycle were plotted against time after drug treatment.
Law, C. L., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., ... & Sauter, G. (2006). Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Research, 66(4), 2328-2337.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H76 | Anti-Human CD70 Recombinant Antibody (Vorsetuzumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
TAB-882 | Anti-Human CD70 Recombinant Antibody (Vorsetuzumab Mafodotin) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
TAB-335LC | Human Anti-CD70 Recombinant Antibody (TAB-335LC) | ELISA | Humanized IgG1, κ |
TAB-342LC | Human Anti-CD70 Recombinant Antibody (TAB-342LC) | FC | Humanized IgG |
TAB-343LC | Human Anti-CD70 Recombinant Antibody (TAB-343LC) | FC | Humanized IgG |
There are currently no Customer reviews or questions for HPAB-AP584-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.